Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Candidemia is a serious bloodstream infection caused by Candida species and represents the most common invasive nosocomial fungal infection worldwide. According to Hemamalini Mohanraj et al. (2024), candidemia, the most prevalent invasive nosocomial fungal infection, has a global incidence of 0.33–6.51 episodes per 1,000 hospital admissions. According to the candidemia epidemiology forecast by Expert Market Research, the disease burden is expected to remain significant due to increasing clinical risk factors.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Candidemia – Number of Cases by Year

Read more about this report - Request a Free Sample

Candidemia Epidemiology Forecast Report Coverage

Expert Market Research's “Candidemia Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of candidemia. It projects the future incidence and prevalence rates of candidemia cases across various populations. The study covers age, gender, and type as major determinants of the candidemia population. The report highlights patterns in the prevalence of candidemia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of candidemia in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Candidemia Understanding: Disease Overview

Candidemia is a serious bloodstream infection caused by Candida species, most commonly Candida albicans, although non-albicans Candida species are increasingly reported. The infection occurs when Candida enters the bloodstream, often through central venous catheters, surgical procedures, prolonged hospitalization, or in individuals with weakened immune systems. Major causative species include Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis, and Candida krusei. If not diagnosed promptly, candidemia can spread to multiple organs and lead to life-threatening complications. Early bloodstream infection detection is critical for improving patient outcomes.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Region

India

High-Risk Population

Intensive care unit (ICU) patients, immunocompromised individuals, patients with central venous catheters, transplant recipients, and individuals with prolonged hospitalization.

Key Diagnostic Method

Blood culture supported by molecular diagnostics and non-culture-based fungal biomarker assays.

Major Risk Factor

Prolonged hospitalization, broad-spectrum antibiotic use, central venous catheterization, immunosuppression, and invasive medical procedures.

Major gap in the market

Delayed diagnosis due to low blood culture sensitivity, slow pathogen identification, and limited access to rapid fungal diagnostics.

Candidemia Epidemiology Perspective

The candidemia epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the candidemia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for candidemia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Hemamalini Mohanraj et al. (2024), candidemia remains the most prevalent invasive nosocomial fungal infection worldwide, with a reported global incidence ranging from 0.33 to 6.51 episodes per 1,000 hospital admissions. As reported by Prof. David W. Denning et al. (2024), approximately 1.565 million people develop candida bloodstream infection or invasive candidiasis annually worldwide, demonstrating a substantial global disease burden.

Gender-Specific Cases of the Disease

As per Arati A. Bhadade et al. (2025), candidemia was more frequently reported among males (57.63%) than females (42.37%), indicating a relatively higher disease burden in men within the evaluated patient population.

Age-Specific Cases of the Disease

According to Arati A. Bhadade et al. (2025), non-Candida albicans candidemia was most common among individuals aged 19–60 years (53.4%), whereas Candida albicans candidemia was predominantly observed in the 0–18-year age group (47%). Based on findings by Silvia Meneghello et al. (2024), candidemia incidence is generally highest among pediatric and elderly populations.

Ethnicity-Wise Cases of the Disease

As documented by Jeffrey D. Jenks et al. (2023), candidemia incidence varies across racial groups in the United States. The overall incidence reached 7.0 cases per 100,000 persons, while Black or African American individuals experienced the highest incidence at 12.3 cases per 100,000 persons, highlighting important epidemiological disparities.

Mortality and Survival Analysis of the Disease

As reported by Prof. David W. Denning et al. (2024), invasive candidiasis and Candida bloodstream infections account for approximately 995,000 deaths annually, corresponding to an estimated 63.6% mortality. As observed by Jon Salmanton-García et al. (2024), overall mortality among candidemia patients was 40.4%, with an attributable mortality of 18.1%.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Candida albicans Candidemia

According to Hemamalini Mohanraj et al. (2024), Candida albicans remains the predominant pathogen, accounting for more than 50% of candidemia cases in several reported series worldwide.

Non-Candida albicans (NAC) Candidemia

As per Hemamalini Mohanraj et al. (2024), the incidence of candidemia caused by Candida tropicalis, Candida glabrata, Candida parapsilosis, and Candida krusei has increased globally, reflecting the growing epidemiological importance of non-Candida albicans species.

Invasive Candidiasis

Based on findings by Silvia Meneghello et al. (2024), invasive candidiasis is a major healthcare-associated fungal infection with increasing worldwide incidence and includes both bloodstream and deep-seated Candida infections.

Candida auris Infection

According to the Science Media Centre (2024), 4,012 Candida auris cases were reported across 36 European countries between 2013 and 2023.

Candidemia – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Candidemia Epidemiology

The candidemia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to Arati A. Bhadade et al. (2025), the United States records approximately 25,000 candidemia cases annually. As documented by Jeffrey D. Jenks et al. (2023), the overall incidence was 7.0 cases per 100,000 persons, increasing to 12.3 cases per 100,000 persons among Black or African American individuals.

Germany

The country contributes to the overall European burden of invasive candidiasis, and continued surveillance supports disease monitoring and healthcare planning.

France

As highlighted by Stéphane Bretagne et al. (2022), France documented 10,886 invasive fungal disease cases between 2012 and 2018. Fungemia incidence increased from 1.03 to 1.19 per 10,000 hospitalization days, while the 1-month mortality rate remained 36.3%. Patients aged 65 years and older increased from 38.4% to 45.3% during the surveillance period.

Italy

Based on findings by Silvia Meneghello et al. (2024), Italy has experienced a threefold increase in candidemia incidence over the past two decades. A cumulative incidence of 2.5 per 1,000 hospital admissions and 30-day mortality rates ranging from 19.8% to 28% have been reported.

Spain

According to the Science Media Centre (2024), Spain reported 1,807 Candida auris cases between 2013 and 2023, representing the highest number among 36 European countries, indicating a substantial regional healthcare burden.

United Kingdom

In the United Kingdom, candidemia continues to represent a significant healthcare-associated bloodstream infection, particularly among hospitalized and critically ill patients. Ongoing surveillance and infection prevention strategies remain important for monitoring disease trends and supporting public health management.

Japan

In Japan, invasive Candida infections continue to contribute to the burden of healthcare-associated fungal diseases, particularly among patients with underlying medical conditions or prolonged hospitalization. Continuous surveillance supports early detection and epidemiological assessment.

India

As per Arati A. Bhadade et al. (2025), candidemia prevalence in India ranges from 1.31% to 3.41%. According to Hemamalini Mohanraj et al. (2024), candidemia incidence is increasing due to factors including intensive care unit admissions, invasive medical devices, and prolonged antibiotic exposure, contributing to a significant healthcare burden.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The regional epidemiology landscape for candidemia is constrained by underdiagnosis, inconsistent surveillance systems, and variability in diagnostic capabilities across healthcare settings. Conventional blood cultures often delay diagnosis, resulting in late initiation of targeted antifungal therapy and unfavorable clinical outcomes. Significant opportunities exist to expand the adoption of rapid molecular diagnostics, fungal biomarker testing, and standardized surveillance programs to improve disease detection and epidemiological reporting. Increasing awareness among healthcare professionals, strengthened antimicrobial stewardship initiatives, and enhanced infection prevention measures in hospitals are expected to improve early diagnosis, patient management, and the overall understanding of candidemia epidemiology across the covered regions.

Candidemia: Treatment Overview

Treatment of candidemia requires the prompt initiation of antifungal therapy, source control, and close clinical monitoring. Echinocandins are generally recommended as first-line treatment for most adults, while fluconazole may be used in clinically stable patients with susceptible Candida species. Removal of infected central venous catheters, when feasible, is an important part of management to reduce the risk of persistent infection. Therapy is typically continued for at least 14 days after documented clearance of the bloodstream and symptom resolution. Comprehensive antifungal therapy combined with appropriate diagnostic evaluation and follow-up blood cultures helps minimize complications and improve survival.

Key Questions Answered

  • What is the current and projected burden of candidemia across the 8 major markets?
  • Which countries across the 8 major markets account for the highest candidemia patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of candidemia across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of candidemia across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of candidemia across the 8 major markets?
  • How do major comorbidities and risk factors influence candidemia epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of candidemia across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the candidemia landscape across the 8 major markets?
  • Which therapeutic areas linked to candidemia are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the candidemia epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on candidemia epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for candidemia across the 8 major markets?

Scope of the Candidemia Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of candidemia based on several factors.
  • Candidemia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The candidemia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Catheter Related Bloodstream Infections Market

Fungal Infections Market

Invasive Fungal Infections Epidemiology Forecast

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us